000008259 001__ 8259
000008259 005__ 20240523050925.0
000008259 024__ $$dUS 201716077213 A
000008259 024__ $$aUS 2019/0112342 A1
000008259 037__ $$aPATENT
000008259 041__ $$aEnglish
000008259 245__ $$aCOMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE
000008259 260__ $$c2019-04-18
000008259 260__ $$g2017-02-10
000008259 336__ $$aPatent
000008259 520__ $$aEmbodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.
000008259 690__ $$aBiological Sciences Division
000008259 691__ $$aMicrobiology
000008259 7011_ $$aMissiakas, Dominique$$uUniversity of Chicago
000008259 7011_ $$aScheewind, Olaf$$uUniversity of Chicago
000008259 7011_ $$aEmolo, Carla$$uUniversity of Chicago
000008259 7011_ $$aThomer, Lena$$uUniversity of Chicago
000008259 7011_ $$uUniversity of Chicago$$aMcAdow, Molly
000008259 7011_ $$aGeurtsen, Jeroen$$uJanssen Pharmaceuticals Inc.
000008259 7011_ $$uJanssen Pharmaceuticals Inc.$$ade Been, Mark
000008259 7121_ $$aUniversity of Chicago
000008259 7121_ $$aJanssen Pharmaceuticals Inc.
000008259 7131_ $$aJanssen Pharmaceuticals Inc.
000008259 7131_ $$aUniversity of Chicago
000008259 7131_ $$aCrucell Holland B.V.
000008259 8564_ $$9ed5b9e07-3850-45d3-8d11-6a630746328a$$s5700692$$uhttps://knowledge.uchicago.edu/record/8259/files/US20190112342.pdf$$ePublic
000008259 909CO $$ooai:uchicago.tind.io:8259$$pGLOBAL_SET
000008259 983__ $$aPatent